|
Oct 9
|
Genmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 4
|
Major Shareholder Announcement
|
|
Sep 30
|
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
|
|
Sep 26
|
Grant of Restricted Stock Units and Warrants to Employees in Genmab
|
|
Aug 28
|
Top High Growth Tech Stocks To Watch In August 2024
|
|
Aug 26
|
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
May 15
|
Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
|
|
May 14
|
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
|
|
May 14
|
Danish biotech says companies should tap into China’s ‘impressive innovation’
|
|
May 13
|
Transactions in Connection with Share Buy-back Program
|
|
Jan 19
|
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
|
Jan 9
|
GMAB or TECH: Which Is the Better Value Stock Right Now?
|
|
Jan 9
|
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Jan 9
|
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
|